Back to search
AML With FLT3 Mutation
Clinical trial pipeline · Data from ClinicalTrials.gov
See which AML With FLT3 Mutation trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which AML With FLT3 Mutation trials you may qualify forThis phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and…
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients wit…
This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in trea…
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin…
The researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with r…
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy t…
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were ref…
This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly di…